Upregulation of endogenous ICAM-1 reduces ovarian cancer cell growth in the absence of immune cells

International Journal of Cancer

Volumn 134, Issue 2, 2014, Pages 280-290

  De Groote, Marloes L ^a   Kazemier, Hinke G ^a   Huisman, Christian ^a   Van Der Gun, Bernardina T F ^a   Faas, Marijke M ^a   Rots, Marianne G ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

artificial transcription factor; cisplatin; epigenetics; tumor suppressor gene; zinc finger

Indexed keywords

CISPLATIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOID ENHANCER FACTOR 1; PROTEIN P53; TRANSCRIPTION FACTOR E2F4; TRANSCRIPTION FACTOR SP1;

ANTIBIOTIC RESISTANCE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME REPRESSION; GENE SEQUENCE; GENE SILENCING; GENETIC EPIGENESIS; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; OVARY CANCER; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN TARGETING; SEQUENCE ANALYSIS; UPREGULATION;

ARTIFICIAL TRANSCRIPTION FACTOR; CISPLATIN; EPIGENETICS; TUMOR SUPPRESSOR GENE; ZINC FINGER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; OVARIAN NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 84887424910     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28375     Document Type: Article

References (48)

1. Ovarian cancer, five-year stage-specific relative survival rates (2004-2008). J Natl Cancer Inst 2011; 103: 1287.
2. Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31: 1869-83.
3. Long EO,. ICAM-1: getting a grip on leukocyte adhesion. J Immunol 2011; 186: 5021-23.
4. Tomita Y, Nishiyama T, Watanabe H, et al. Expression of intercellular adhesion molecule-1 (ICAM-1) on renal-cell cancer: possible significance in host immune responses. Int J Cancer 1990; 46: 1001-6.
5. Arnold JM, Cummings M, Purdie D, et al. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas. Br J Cancer 2001; 85: 1351-58. (Pubitemid 33081932)
6. Terol MJ, Lopez-Guillermo A, Bosch F, et al. Expression of the adhesion molecule ICAM-1 in non-hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance. J Clin Oncol 1998; 16: 35-40. (Pubitemid 28041576)
7. Maeda K, Kang SM, Sawada T, et al. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep 2002; 9: 511-14.
8. Shirai A, Furukawa M, Yoshizaki T,. Expression of intercellular adhesion molecule (ICAM)-1 in adenoid cystic carcinoma of the head and neck. Laryngoscope 2003; 113: 1955-60. (Pubitemid 37409684)
9. Natali P, Nicotra MR, Cavaliere R, et al. Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res 1990; 50: 1271-8. (Pubitemid 20084022)
10. Koyama S, Ebihara T, Fukao K,. Expression of intercellular adhesion molecule 1 (ICAM-1) during the development of invasion and/or metastasis of gastric carcinoma. J Cancer Res Clin Oncol 1992; 118: 609-14.
11. Ogawa Y, Hirakawa K, Nakata B, et al. Expression of intercellular adhesion molecule-1 in invasive breast cancer reflects low growth potential, negative lymph node involvement, and good prognosis. Clin Cancer Res 1998; 4: 31-6. (Pubitemid 28062874)
12. Schroder C, Witzel I, Muller V, et al. Prognostic value of intercellular adhesion molecule (ICAM)-1 expression in breast cancer. J Cancer Res Clin Oncol 2011; 137: 1193-201.
13. Matsuoka H, Eura M, Chikamatsu K, et al. Low doses of anticancer drugs increase susceptibility of tumor cells to lysis by autologous killer cells. Anticancer Res 1995; 15: 87-92.
14. Ramesh G, Reeves WB,. TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 2002; 110: 835-42.
15. Carroll D, Morton JJ, Beumer KJ, et al. Design, construction and in vitro testing of zinc finger nucleases. Nat Protoc 2006; 1: 1329-41.
16. Sera T,. Zinc-finger-based artificial transcription factors and their applications. Adv Drug Deliv Rev 2009; 61: 513-26.
17. Stolzenburg S, Rots MG, Beltran AS, et al. Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012; 40: 6725-40.
18. Huisman C, Wisman GB, Kazemier HG, et al. Functional validation of putative tumor suppressor gene C13ORF18 in cervical cancer by artificial transcription factors. Mol Oncol 2013; 7: 669-79.
19. Beltran AS, Blancafort P,. Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 2011; 6: 224-35.
20. Magnenat L, Blancafort P, Barbas CF III, et al. In vivo selection of combinatorial libraries and designed affinity maturation of polydactyl zinc finger transcription factors for ICAM-1 provides new insights into gene regulation. J Mol Biol 2004; 341: 635-49. (Pubitemid 39118402)
21. Davies BR, Steele IA, Edmondson RJ, et al. Immortalisation of human ovarian surface epithelium with telomerase and temperature-sensitive SV40 large T antigen. Exp Cell Res 2003; 288: 390-2.
22. Ziegler-Heitbrock HW, Thiel E, Futterer A, et al. Establishment of a human cell line (mono mac 6) with characteristics of mature monocytes. Int J Cancer 1988; 41: 456-61. (Pubitemid 18080805)
23. Gorringe KL, Chin SF, Pharoah P, et al. Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer. Carcinogenesis 2005; 26: 923-30. (Pubitemid 41214321)
24. Blancafort P, Magnenat L, Barbas CF, et al. Scanning the human genome with combinatorial transcription factor libraries. Nat Biotechnol 2003; 21: 269-74. (Pubitemid 36314810)
25. van der Gun BT, de Groote ML, Kazemier HG, et al. Transcription factors and molecular epigenetic marks underlying EpCAM overexpression in ovarian cancer. Br J Cancer 2011; 105: 312-19.
26. Weinmann AS, Farnham PJ,. Identification of unknown target genes of human transcription factors using chromatin immunoprecipitation. Methods 2002; 26: 37-47. (Pubitemid 34969216)
27. Murakami S, Morioka T, Nakagawa Y, et al. Expression of adhesion molecules by cultured human glomerular endothelial cells in response to cytokines: comparison to human umbilical vein and dermal microvascular endothelial cells. Microvasc Res 2001; 62: 383-91. (Pubitemid 33027923)
28. Webb DS, Mostowski HS, Gerrard TL,. Cytokine-induced enhancement of ICAM-1 expression results in increased vulnerability of tumor cells to monocyte-mediated lysis. J Immunol 1991; 146: 3682-6.
29. Jonjic N, Alberti S, Bernasconi S, et al. Heterogeneous susceptibility of human melanoma clones to monocyte cytotoxicity: role of ICAM-1 defined by antibody blocking and gene transfer. Eur J Immunol 1992; 22: 2255-60.
30. Burno DK, Kyprianou N, Sartor WM, et al. Transfection of a murine fibrosarcoma with intercellular adhesion molecule-1 enhances the response to adoptive immunotherapy. Surgery 1995; 118: 237-43; discussion 243-4.
31. Wei K, Wilson JG, Jurgensen CH, et al. Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity. Gene Ther 1996; 3: 531-41. (Pubitemid 26197543)
32. Uzendoski K, Kantor JA, Abrams SI, et al. Construction and characterization of a recombinant vaccinia virus expressing murine intercellular adhesion molecule-1: induction and potentiation of antitumor responses. Hum Gene Ther 1997; 8: 851-60. (Pubitemid 27231913)
33. D'Angelica M, Tung C, Allen P, et al. Herpes simplex virus (HSV)-mediated ICAM-1 gene transfer abrogates tumorigenicity and induces anti-tumor immunity. Mol Med 1999; 5: 606-16. (Pubitemid 32936951)
34. Kikuchi T, Joki T, Akasaki Y, et al. Induction of antitumor immunity using intercellular adhesion molecule 1 (ICAM-1) transfection in mouse glioma cells. Cancer Lett 1999; 142: 201-6. (Pubitemid 29304577)
35. Tachimori A, Yamada N, Sakate Y, et al. Up regulation of ICAM-1 gene expression inhibits tumour growth and liver metastasis in colorectal carcinoma. Eur J Cancer 2005; 41: 1802-10. (Pubitemid 41132644)
36. van der Gun BT, Melchers LJ, Ruiters MH, et al. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010; 31: 1913-21.
37. Sood AK, Fletcher MS, Gruman LM, et al. The paradoxical expression of maspin in ovarian carcinoma. Clin Cancer Res 2002; 8: 2924-32. (Pubitemid 35025740)
38. Strell C, Lang K, Niggemann B, et al. Neutrophil granulocytes promote the migratory activity of MDA-MB-468 human breast carcinoma cells via ICAM-1. Exp Cell Res 2010; 316: 138-48.
39. Rosette C, Roth RB, Oeth P, et al. Role of ICAM1 in invasion of human breast cancer cells. Carcinogenesis 2005; 26: 943-50. (Pubitemid 41214323)
40. Rebar EJ, Huang Y, Hickey R, et al. Induction of angiogenesis in a mouse model using engineered transcription factors. Nat Med 2002; 8: 1427-32. (Pubitemid 36019428)
41. Hu X, Barnum SR, Wohler JE, et al. Differential ICAM-1 isoform expression regulates the development and progression of experimental autoimmune encephalomyelitis. Mol Immunol 2010; 47: 1692-700.
42. Yu W, Jin C, Lou X, et al. Global analysis of DNA methylation by methyl-capture sequencing reveals epigenetic control of cisplatin resistance in ovarian cancer cell. PLoS One 2011; 6: e29450.
43. Hellebrekers DM, Castermans K, Vire E, et al. Epigenetic regulation of tumor endothelial cell energy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res 2006; 66: 10770-7. (Pubitemid 44876972)
44. Easwaran HP, Van Neste L, Cope L, et al. Aberrant silencing of cancer-related genes by CpG hypermethylation occurs independently of their spatial organization in the nucleus. Cancer Res 2010; 70: 8015-24.
45. Vanden Berghe W,. Epigenetic impact of dietary polyphenols in cancer chemoprevention: lifelong remodeling of our epigenomes. Pharmacol Res 2012; 65: 565-76.
46. Jones A, Lechner M, Fourkala EO, et al. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics 2010; 2: 9-38.
47. Juergens RA, Wrangle J, Vendetti FP, et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011; 1: 598-7.
48. Yu Y, Zeng P, Xiong J, et al. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic ezrin gene. PLoS One 2010; 5: e12710.